Every three years the FOPH reviews all pharmaceuticals on the specialities list to check whether they still meet the requirements for inclusion.
- Triennial review of pharmaceuticals 2025
- Triennial review of pharmaceuticals 2024
- Triennial review of pharmaceuticals 2023
- Triennial review of pharmaceuticals 2022
- Triennial review of pharmaceuticals 2021
- Triennial review of pharmaceuticals 2020
- Triennial review of pharmaceuticals 2019
- Triennial review of pharmaceuticals 2018
- Triennial review of pharmaceuticals 2017
- General information
- Current notifications from the FOPH on the triennial review of inclusion requirements for pharmaceuticals
Triennial review of pharmaceuticals in 2025
List of pharmaceuticals subject to appeal
The pharmaceuticals which were the object of appeals in the Federal Administrative Court are published in the List of pharmaceuticals subject to an appeal against a decision of the FOPH (see page Information related to the specialities list).
Triennial review of pharmaceuticals in 2024
Lists of the originals, generics, co-marketing and biosimilars with price reductions as of 1 December 2024 or later, subject to possible changes.
Lists of the originals, generics, co-marketing and biosimilars without price reductions as of 1 December 2024 or later, subject to possible changes.
Triennial review of pharmaceuticals in 2023
Lists of the originals, generics, co-marketing and biosimilars with price reductions as of 1 December 2023 or later, subject to possible changes. (in German and French only)
Lists of the originals, generics, co-marketing and biosimilars without price reductions as of 1 December 2023 or later, subject to possible changes. (in German and French only)
Triennial review of pharmaceuticals in 2022
Lists of the originals, generics, co-marketing and biosimilars with price reductions as of 1 December 2022 or later, subject to possible changes. (in German and French only)
Lists of the originals, generics, co-marketing and biosimilars without price reductions as of 1 December 2022 or later, subject to possible changes. (in German and French only)
Triennial review of pharmaceuticals in 2021
Lists of the originals, generics, co-marketing and biosimilars with price reductions as of 1 December 2021 or later, subject to possible
changes. (in German and French only)
Lists of the originals, generics, co-marketing and biosimilars without price reductions as of 1 December 2021 or later, subject to possible changes. (in German and French only)
Triennial review of pharmaceuticals in 2020
Lists of the originals, generics, co-marketing and biosimilars with price reductions as of 1 December 2020 or later, subject to possible changes. (in German and French only)
Lists of the originals, generics, co-marketing and biosimilars without price reductions as of 1 December 2020 or later, subject to possible changes. (in German and French only)
Triennial review of pharmaceuticals in 2019
Complete list of the pharmaceuticals with a reduced price resulting from the review in 2019 and complete list of the pharmaceuticals without a price reduction resulting from the review in 2019, subject to possible changes.
Triennial review of pharmaceuticals in 2018
Complete list of the pharmaceuticals with a reduced price (as reviewed in 2018) and lists of the pharmaceuticals without a price reduction (as reviewed in 2018), subject to possible changes.
Triennial review of pharmaceuticals in 2017
Complete list of the pharmaceuticals with a reduced price (as reviewed in 2017) and lists of the pharmaceuticals without a price reduction (as reviewed in 2017), subject to possible changes.
General information
Pharmaceuticals are assigned to one of three groups based on the therapeutic group of the specialities list they belong to. Each group is reviewed every three years:
Group A | Group B | Group C |
---|---|---|
Gastroenterology (04) Metabolism (07) Antidotes (15) Cation exchangers (16) Gastroenterology, complementary medicine (54) Metabolism, complementary medicine (57) |
Nervous system (01) Kidneys and water balance (05) Blood (06) Dermatology (10) Odontostomatology (13) Diagnostics (14) Nervous system, complementary medicine (51) Kidneys and water balance, complementary medicine (55) Blood, complementary medicine (56) Dermatology, complementary medicine (60) |
Cardiovascular (02) Pulmonary and respiratory (03) Infectious diseases (08) Gynaecology (09) Ophthalmology (11) Otorhinolaryngology (12) Other pharmaceuticals, complementary medicine (20) Cardiovascular, complementary medicine (52) Pulmonary and respiratory, complementary medicine (53) Infectious diseases, complementary medicine (58) Gynaecology, complementary medicine (59) Ophthalmology, complementary medicine (61) Otorhinolaryngology, complementary medicine (62) |
Current notifications from the FOPH on the triennial review of inclusion requirements for pharmaceuticals
Last modification 20.12.2024
Contact
Federal Office of Public Health FOPH
Health and Accident Insurance Directorate
Review of pharmaceuticals Section
Schwarzenburgstrasse 157
3003
Bern
Switzerland
Tel.
+41 58 483 96 48